Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Duda

Showing results (261-270 of 338) with videos related to

Pageof 34
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent GlioblastomaElizabeth R Gerstner, Kyrre E Emblem, Ken Chang, et al.
NPJ Precision Oncology|October 31, 2018
Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapyTheodore S Hong, Clemens Grassberger, Beow Y Yeap, et al.
Scientific Reports|November 22, 2018
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
Scientific Reports|June 15, 2019
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
NPJ Breast Cancer|August 26, 2021
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker studyRomualdo Barroso-Sousa, Tanya E Keenan, Tianyu Li, et al.
Oncotarget|April 23, 2021
Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenibYehia I Mohamed, Sunyoung Lee, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2022
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling InhibitionJohn D Martin, Ryan M Lanning, Vikash P Chauhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Cancers|October 14, 2023
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular CarcinomaBetul Gok Yavuz, Saumil Datar, Shadi Chamseddine, et al.
Pageof 34

Showing results (261-270 of 338) with videos related to

Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent GlioblastomaElizabeth R Gerstner, Kyrre E Emblem, Ken Chang, et al.
NPJ Precision Oncology|October 31, 2018
Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapyTheodore S Hong, Clemens Grassberger, Beow Y Yeap, et al.
Scientific Reports|November 22, 2018
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
Scientific Reports|June 15, 2019
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRIK Ina Ly, Bella Vakulenko-Lagun, Kyrre E Emblem, et al.
NPJ Breast Cancer|August 26, 2021
Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker studyRomualdo Barroso-Sousa, Tanya E Keenan, Tianyu Li, et al.
Oncotarget|April 23, 2021
Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenibYehia I Mohamed, Sunyoung Lee, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2022
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling InhibitionJohn D Martin, Ryan M Lanning, Vikash P Chauhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2026
Erratum: Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular SchwannomasJaishri O Blakeley, Xiaobu Ye, Dan G Duda, et al.
Cancers|October 14, 2023
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular CarcinomaBetul Gok Yavuz, Saumil Datar, Shadi Chamseddine, et al.
Pageof 34